Methylation of promoter is a risk factor for tumor stage and survival in clear cell renal cell carcinoma.

Inactivation of tumor suppressor gene serine-threonine kinase 11 () in clear cell renal cell carcinoma (ccRCC) has been demonstrated; however, the mechanism of this inactivation remains to be investigated. To investigate whether epigenetic alteration plays a role in the inactivation of in RCC, the present study aimed to investigate the methylation status of the promoter and its association with tumor stage and survival in ccRCC patients. Paraffin-embedded specimens were obtained from 42 ccRCC patients.

The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.

Aim: This study aimed to investigate the methylation status of EGF-like and two follistatin-like domains 2 (TMEFF2) promoter and its correlation with tumor stage and survival outcome in renal cell carcinoma (RCC).

Materials And Methods: Paraffin-embedded specimens from 42 RCC patients were analyzed for TMEFF2 methylation by methylation-specific polymerase chain reaction. The distribution of TNM/AJCC stages and survival time were compared among patients with unmethylated and methylated TMEFF2.